Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CROMOLYN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CROMOLYN SODIUM.
ACUVUE THERAVISION WITH KETOTIFEN vs CROMOLYN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Mast Cell Stabilizer